Publication: Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
No Thumbnail Available
Identifiers
Date
2017-12-15
Authors
Pulido, Federico
Ribera, Esteban
Lagarde, Maria
Perez-Valero, Ignacio
Palacios, Rosario
Iribarren, Jose A.
Payeras, Antoni
Domingo, Pere
Sanz, Jose
Cervero, Miguel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford univ press inc
Metrics
Export
Abstract
Background. Our objective was to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides for maintenance of human immunodeficiency virus type 1 (HIV-1) suppression.Methods. This was a multicenter, open-label, noninferiority trial (margin 12%). Patients with HIV-1 RNA
Description
MeSH Terms
Adult
Adult
Anti-HIV Agents
CD4 Lymphocyte Count
Darunavir
Dideoxynucleosides
Emtricitabine
Female
HIV Infections
HIV Protease Inhibitors
HIV-1
Humans
Lamivudine
Male
Medication Therapy Management
Middle Aged
RNA, Viral
Ritonavir
Tenofovir
Viral Load
Adult
Anti-HIV Agents
CD4 Lymphocyte Count
Darunavir
Dideoxynucleosides
Emtricitabine
Female
HIV Infections
HIV Protease Inhibitors
HIV-1
Humans
Lamivudine
Male
Medication Therapy Management
Middle Aged
RNA, Viral
Ritonavir
Tenofovir
Viral Load
DeCS Terms
CIE Terms
Keywords
darunavir/ritonavir, lamivudine, switch, dual therapy, Non-inferiority trial, Reverse-transcriptase inhibitor, Virologically stable patients, Boosted protease inhibitor, Antiretroviral therapy, Coformulated elvitegravir, 2 nucleos(t)ides, Phase 3b, Simplification, Hiv